Nuvation Bio Inc - Asset Resilience Ratio
Nuvation Bio Inc (NUVB) has an Asset Resilience Ratio of 66.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Nuvation Bio Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Nuvation Bio Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Nuvation Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Nuvation Bio Inc (NUVB) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $408.34 Million | 66.91% |
| Total Liquid Assets | $408.34 Million | 66.91% |
Asset Resilience Insights
- Very High Liquidity: Nuvation Bio Inc maintains exceptional liquid asset reserves at 66.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nuvation Bio Inc Industry Peers by Asset Resilience Ratio
Compare Nuvation Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Nuvation Bio Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Nuvation Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.38% | $365.12 Million | $594.82 Million | -24.99pp |
| 2024-12-31 | 86.38% | $466.97 Million | $540.63 Million | -5.11pp |
| 2023-12-31 | 91.48% | $568.56 Million | $621.48 Million | +8.18pp |
| 2022-12-31 | 83.30% | $559.91 Million | $672.14 Million | +1.75pp |
| 2021-12-31 | 81.55% | $632.97 Million | $776.15 Million | -2.31pp |
| 2020-12-31 | 83.86% | $186.00 Million | $221.79 Million | -11.55pp |
| 2019-12-31 | 95.41% | $115.40 Million | $120.95 Million | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more